Aktienanalyse zu IN8bio Inc (INAB)INABIN8bio Inc

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

IN8BIO, Inc. is not a good buy right now due to its current price of $0.97, which is significantly below its 52-week high of $2.73, indicating a potential for further decline. The RSI is at 44.99, suggesting it is nearing oversold territory but not yet a strong buy signal. Additionally, the company has reported consistent losses, with a net income of -$6.16 million in Q4 2024, and a forward P/E ratio of 0, indicating no earnings growth expectations. The recent insider selling trend has increased by 2792.50%, which raises concerns about the company's future performance.